Swiss giant Novartis is cutting 64 jobs at its Dorval facilities as part of a restructuring that began last April, including more than 30 today, Le Journal learned.
“This restructuring will affect approximately 7 employees (as of October 14, 2022), 21 employees (as of October 28, 2022) and 36 employees (as of November 4, 2022)”, confirmed to the Journal Claudja Joseph, manager Principal, Associate Engagement and Novartis External.
“This will allow us to reduce duplication of organizational structures and create a leaner, learning organization, improving patient and customer orientation,” she added.
Novartis integrates Pharma and Oncology business units into one and even Innovative Medicines (IM) division to serve its markets.
Without providing details, Novartis assures that she will do everything to help affected employees find new employment within the company or outside.
“We recognize the impact that these changes will have on our staff and will ensure that all the partners concerned in a fair and transparent way, in particular by helping them to find a new job internally or externally”, concludes Claudja Joseph from Novartis.
You have any scoop to send us?
Do you have something to tell us about this story?
Do you have a scoop that our readers might be interested in?
Katrine Johns has been a reporter on the news desk since 2013. Before that she wrote about young adolescence and family dynamics for Styles and was the legal affairs correspondent for the Metro desk. Before joining The Gal Post, Katrine Johns worked as a staff writer at the Village Voice and a freelancer for Newsday, The Wall Street Journal, GQ and Mirabella. To get in touch, contact me through my email@example.com 1-800-268-7128